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Abstract
Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and
affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic
mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are
necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of
endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA4), an anti-inflammatory and pro-resolving lipid
mediator that we have recently characterized as an estrogen receptor agonist. LXA4 treatment significantly reduced
endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1b and IL-6, as well as the angiogenic factor
VEGF. LXA4 also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated
peritoneal fluid Prostaglandin E2 (PGE2) levels. Besides its anti-inflammatory effects, LXA4 differentially regulated the
expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating
transforming growth factor (TGF)-b isoform expression within endometriotic lesions and in peritoneal fluid cells. We also
report for first time that LXA4 attenuated aromatase expression, estrogen signaling and estrogen-regulated genes
implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA4 was
administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets
for the treatment of endometriosis and suggest a pleotropic effect of LXA4 on disease progression, by attenuating pro-
inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as
downstream proliferative pathways.
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Introduction
Endometriosis is a gynecological disorder, defined as the
presence of endometrial-like tissue outside the uterine cavity,
primarily on the pelvic peritoneum, ovaries, pouch of Douglas
and rectovaginal septum. Endometriosis affects approximately
10% of women of reproductive age and is associated with local
inflammation, the main clinical features being chronic pelvic pain,
pain during intercourse and infertility [1]. The pathophysiology of
this estrogen-dependent disease is enigmatic, with a poor
correlation between the observed severity of the disease and the
reported symptoms [2,3]. The medical treatment of endometriosis
includes progestagens, gonadotropin-releasing hormone agonists
and oral contraceptives. However, the use of these therapeutics is
limited due to the high cost, adverse side effects and recurrence of
the disease after discontinuation of therapy [4,5]. Thus, there is an
unmet need for new drugs which inhibit the progression of
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endometriosis and alleviate pain and infertility, without affecting
ovulation.
The progression of endometriosis is characterized by marked
alternations in estrogen metabolism and pro-inflammatory medi-
ator levels and activity [6,7]. In the peritoneal cavity activated
macrophages are the major source of IL-1b, IL-6, IL-8 and TNF-
a and altered expression of these proinflammatory cytokines has
been described in the peritoneal fluid of women with endometri-
osis. The disease is not only characterized by the presence of
inflammatory lesions, but also by abnormal proliferation and
growth of ectopic endometrial tissue [8,9]. In endometrial
implants, vascular endothelial growth factor (VEGF) and trans-
forming growth factor-beta (TGF-b) induce neo-vascularization
[2,6,10]. Moreover, IL-1b and TNF-a have been shown to
increase the expression of MMPs in endometriotic implants,
promoting matrix remodeling [11].
Lipoxins are endogenous eicosanoids, generally produced via a
transcellular biosynthetic pathway, which exhibit both anti-
inflammatory and pro-resolving properties [12]. LXA4 mediates
anti-inflammatory activities through multiple receptors in vivo, the
best characterized being lipoxin A4 receptor (ALX)/formyl
peptide receptor 2 (FPR2) [13]. LXA4 binds with high affinity to
ALX/FPR2, expressed by myeloid and non-myeloid cells [14,15].
Other more recently characterized receptors are GPR32 [16] and
the arylhydrocarbon receptor [17], the later study having used
murine hepatoma cells. We have recently demonstrated that this
lipid mediator is estrogenic in vitro and in vivo, binding to and
signaling via ERa in endometrial epithelial cells [18], where it can
counteract some 17b-estradiol (E2)-mediated responses. Lipoxins
are known to be potent chemo-attractants for peripheral blood
monocytes and induce non-phlogistic phagocytosis of apoptotic
neutrophils by macrophages [19]. Macrophage recruitment would
thus lead to the resolution of inflammation which is important for
the restoration of tissue homeostasis [20]. However, macrophages,
being a major source of prostaglandin E2 (PGE2), may also
promote endometriosis [21]. Besides being implicated in symp-
tomatic inflammation and pain, PGE2 plays a key role in the
pathology by inducing E2 production in endometriotic cells.
Recent data have suggested a protective role of LXA4 in the
development and progression of experimental endometriosis in
mice [22,23]. However, the mechanisms by which LXA4 mediates
this action remain poorly understood. The aim of the present
study was to better understand the mechanisms underlying this
effect and to establish whether LXA4 is protective for established
endometriosis, focusing on inflammatory and angiogenic media-




All experimental procedures were approved by Canton de Vaud
veterinary authorizations (protocol numbers 1884.2 and 2655.0).
All surgery was performed under anesthesia and all efforts made to
minimize suffering. Seven week old wild-type female C57BL/6J
mice were purchased from Elevage Janvier, France, randomly
housed ten per cage for one week prior to surgery and fed on
mouse diet and water ad libitum. The animal house temperature
was maintained at 26uC with light/dark cycles of 12 h under
controlled humidified conditions. Age-matched mice were syn-
chronized prior to all experiments, by keeping them in mixed
cages for at least 1 week prior to surgery (Lee-Boot Effect). Mice
were then caged 5 per cage, randomly assigned to each
experimental group and underwent surgery at 8 weeks of age.
Cycle stage was checked by microscopic examination of vaginal
swabs at day 2, day 10 and day 21 and at day 21 the majority of
mice were in estrus stage.
Surgical induction of endometriosis and in vivo
treatment
The surgical method to induce endometriosis was modified
from Vernon and Wilson [24] and Cumming and Metcalf [25].
Mice were randomly divided into three groups; sham, vehicle-
treated with endometriosis (‘Veh’) and LXA4-treated with
endometriosis (‘LXA4’). Briefly, mice were anesthetized using
Xylazine (10 mg/kg, Rompun, Bayer Healthcare, Germany) and
Ketamine (100 mg/kg, Ketavet, Phamacia&Upjohn GmbH,
Germany) and their weight was recorded. Uterine tissue from
one donor mouse was transplanted into two recipient mice. Mice
underwent laparotomy by a midventral incision. Uterine horns
were excised from age-matched syngeneic donor mice and kept in
37uC pre-warmed DMEM-F12 (Invitrogen, Switzerland) medium
supplemented with penicillin (100 U/mL, Sigma) and streptomy-
cin (100 mg/mL, Sigma) in petri dishes, opened longitudinally and
six uniform, full thickness 2-mm punches were made using a
dermal biopsy punch (Stiefel, Germany). Six endometrial biopsies
were sutured to the peritoneal wall of recipient mice, three on each
side. Sham mice were operated on identically except that silk
sutures alone were placed on the peritoneal wall in the same
positions as other groups. The abdominal incision was closed by a
continuous suture and the skin with individual knots. Mice were
kept warm and maintained under observation until full recovery.
LXA4 (Calbiochem, USA) was administered once daily by
intraperitoneal (IP) injection at 5 mg/kg, a concentration demon-
strated to be effective in preliminary experiments, in 200 ml sterile
phosphate buffered saline (PBS, Laboratrium Dr. Bichsel AG,
Switzerland). Sham and Veh groups received 200 ml EtOH/PBS
IP in an identical manner. To assess the effect of LXA4 on de novo
endometriosis, 5 mg/kg was administered once daily by IP
injection 1 day prior (D21) to surgery with treatment given daily
thereafter until day 20. To assess the effect of LXA4 on established
endometriosis treatment was commenced 6 days after disease
induction (D+6) and performed in an identical manner. Mice were
monitored daily and no adverse effects were observed based on
food consumption, body weight, grooming behavior, or physical
activity.
Evaluation of endometriotic lesions and sample
collection
Mice were weighed and sacrificed by cervical dislocation under
anaesthesia on the morning of day 21. 1 ml of sterile PBS was
injected IP, the abdominal cavity was gently massaged and the
peritoneal fluid was collected by centrifugation. Peritoneal lavage
supernatants were transferred to sterile eppendorfs and stored at2
80uC for ELISAs, while cell pellets were stored at 280uC for
subsequent qRT-PCR analysis. Ectopic endometrial lesions were
measured using calipers in two perpendicular diameters and the
volume was calculated (V= 4/3pr2R, where r and R are two
perpendicular radii and r,R). Lesions were flash frozen in liquid
Nitrogen for qRT-PCR and stored at 280uC or fixed in 10%
neutral buffered formalin for 24 h and embedded in paraffin for
immunohistochemistry.
RNA isolation and qRT-PCR
Total RNA from individual endometriotic lesions and perito-
neal fluid cells (PFCs) were extracted with TRIzol reagent
(Invitrogen, USA) as per the manufacturer’s instructions.
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5–10 mg endometriotic lesion tissue and pelleted PFCs were
homogenized using a polytron (VWR International AG, Switzer-
land) in 600 and 800 ml of TRIzol respectively, followed by
chloroform/isopropanol extraction. RNA concentration and
purity were checked using a Nanodrop ND2000 spectrophotom-
eter (Thermo Scientific, USA). RNA samples with 260/280 nm
absorbance ratio of ,2 (,1.8 for cDNA) were subjected to
expression analyses. DNase (Promega, USA) treatment was
followed by reverse transcription (RT), performed using the
iScriptTM cDNA Synthesis kit (Bio-rad Laboratories, USA)
according to the manufacturer’s instructions. Quantitative PCR
was performed using a Rotor-Gene 6000 (Corbett Research,
Australia) instrument and SYBR Green technology (SensiMixTM
SYBR kit, Quantace). Intron spanning and exon-specific primers
were designed manually and synthesized by Microsynth (Switzer-
land). Primers were initially validated by executing standard curves
(primer with single melting curve peak and amplification efficiency
.80% were considered) and by confirming product size on an
agarose gel with ethidium bromide staining. Primer sequences are
listed in Tableoˆ 1. The DDCt method [26] was used to calculate
relative changes in mRNA expression. Data were normalized with
GAPDH as housekeeping gene and 100% assigned to the vehicle-
treated experimental group.
Cytokine and PGE2 quantification
Peritoneal lavage supernatants were thawed on ice and
centrifuged at 12000rpm for 59 at 4uC. The Biorad protein
quantification kit (Bio-Rad Laboratories, USA) was used to
normalize protein content. Samples containing 50 mg of total
protein were assayed. VEGF and IL-1b cytokine levels were
measured by ELISA according to the manufacturer’s instructions
(R&D Systems, USA).
Peritoneal fluid samples were diluted using water and methanol.
The mixture was acidified with 2N HCl to pH 3.5 and applied to
a C18 cartridge (Sep-Pak Classic, WatersH, IT) which was
preactivated with methanol and water. The columns were washed
with water and hexane, eluted by adding methyl-formate (1:1
methanol and formic acid) and evaporated under a nitrogen
stream. The residue was reconstituted in EIA Buffer and PGE2
quantification was performed using a monoclonal EIA kit
(Cayman Chemical company, USA). Briefly, standards and
samples containing 250 mg total protein were incubated overnight
at 4uC in a plate pre-coated with goat anti-mouse IgG, with PGE2
Tracer (PGE2-Acetylcholineesterase conjugate) and mouse anti-
PGE2 monoclonal antibody. The plate was subsequently washed,
Ellman’s reagent (5,59-dithio-bis-(2-nitrobenzoic acid) and acetyl-
choline added and the absorbance was read at 405 nm.
Histology and immunohistochemistry
Formalin fixed and paraffin embedded tissues were cut into
5 mm sections and mounted on SuperFrost Ultras Plus glass slides
(Thermo Scientific, Germany). For gross examination sections
were stained with hematoxylin (Merck Chemicals, Switzerland)
and eosin (HE staining) following standard protocols and mounted
using permanent mounting medium (Eukitt, Sigma-Aldrich,
Switzerland). For immunohistochemical staining, sections were
deparaffinized (55uC for 209) and rehydrated by serial bathing in
xylene and EtOH solutions, washed in PBS for 59 and antigen
retrieval performed using Tris-EDTA pH 9 solution. Slides were
incubated in 3% H2O2 solution for 109 to block endogenous
peroxidases, washed, incubated at RT in blocking buffer (PBS-4%
BSA-0.05% Tween 20) for 309 followed by washing. Diluted
primary antibody (in PBS-1% BSA) was applied to the slides for
909. The following antibodies were used: rabbit anti-mouse COX-
2 (Cayman Chemical company, USA) and anti-mouse ERa
(Serotec, USA). For COX-2 immunohistochemistry, inflamed
joint sections from mice with induced arthritis were used to
optimize the staining and for ERa, eutopic uterus sections were
Table 1.
Gene Symbol Forward Sequence (59–39) Reverse Sequence (59–39)
m CCND-1 CACCAATCTCCTCAACGACC CTCACAGACCTCCAGCATCC
m COX-2 CAGGTCATTGGTGGAGAGGTG TGCTCATCACCCCACTCAGG
m CYP19a1 CATTATCAGCAAGTCCTCAAGC GAGGGTCAACACATCCACG
m ERa GATGAAAGGCGGCATACGG CAGGGCTATTCTTCTTAGTGTGC
m FPR2 GTGTGCTGGGCAATGGAC CTGAGCCCAGACTGGATGC
m GAPDH GTCGGTGTGAACGGATTTG AAGATGGTGATGGGCTTCC
m GREB-1 GCACCACTTTGTTTTCAGCC GTTGTCGGTGTGAAGGTTGG
m HIF-1a TCACCAGACAGAGCAGGAAA GTCACCTGGTTGCTGCAATA
m IL-1b GGGCCTCAAAGGAAAGAATC CTCTGCTTGTGAGGTGCTGA
m IL-6 AGAAGGGCCTGGAATGAAAC AAGACCCTGCTGGAACAAGA
m MMP-2 CCAAGGTGGAAATCAGAGACA CGAAGGGC ATACAAAAGCAAC
m MMP-3 CCTGGAACAGTCTTGGCTC CCTTGGCTGAGTGGTAGAGTC
m MMP-9 GCCCTGGAACTCACACGACA TTGGAAACTCACACGCCAGAAG
m MRP4 CCTGTTCCAACTGTGTATCTGTC GCACCATCTCACCATCTTTG
m c-Myc GCAGACAGCCACGACGATG CTCGCTCTGCTGTTGCTGG
m TGF-b1 GAACCAAGGAGACGGAATACAG CCATGAGGAGCAGGAAGG
m TGF-b2 CCTGCTAATGTTGTTGCCC CAATGTAAAGAGGGCGAAGG
m TGF-b3 CGCAACCTGGAGGAGAACTG CGTGCTATGGGTTGTGTCTG
m VEGF AGTCCCATGAAGTGATCAAGTTCA ATCCGCATGATCTGCATGG
doi:10.1371/journal.pone.0089742.t001
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used as a positive control. Negative control sections were
incubated alongside with the respective isotype control antibodies
in dilution buffer, to control for specificity. After washing,
horseradish peroxidase-conjugated secondary antibodies (Cell
Signaling Technology, USA) was added for 209 with the
diaminobenzidine (DAB), Dako kit, Denmark) substrate. Coun-
terstaining was performed with hematoxylin, followed by dehy-
dration steps and mounting. Slides were analyzed with a Nikon
Eclipse E800 microscope and digital DXM1200 camera using
ACT-1 software.
Zymography
Gelatinolytic activities of MMP-2 and MMP-9 were assessed
using zymography. Briefly, 20 ml of peritoneal fluid sample, whose
protein content had been normalized as detailed above, was mixed
with non reducing loading buffer, loaded and electrophoresed
through 8% SDS polyacrylamide gels containing 0.1% gelatin.
Gels were then washed with renaturation buffer (2.5% Triton X-
100) for 409 followed by incubation in zymogram incubation
buffer (50 mM Tris pH 7.8, 0.15 M NaCl, 10 mM CaCl2, 0.02%)
for 20 h at 37uC. Subsequently, staining with 0.25% Coomassie
G250, 30% methanol, 10% acetic acid for 309 and destaining with
30% methanol, 10% acetic acid was performed until white bands
appeared over blue background. Gels were scanned and white
bands were quantified using Gel Analyzer software. The relative
enzymatic activity was calculated as a percentage, samples from
Veh-treated mice being assigned 100%.
Data analysis & statistics
At least 3 independent experiments were performed for each set
of data with 10–15 mice per experimental group depending on the
requirements of the experiments. When repeated experiments
yielded similar results, the results of one representative experiment
are shown. Results are expressed as mean 6 SEM. Statistical
analysis was performed using unpaired t-tests for comparisons
between 2 groups (analysis of endometriotic lesions, comparing
Veh and LXA4) and one way analysis of variance (ANOVA) along
with Tukey’s multiple comparison tests to check the level of
significance among multiple treatment groups (analysis of PFCs
and PF, comparing sham, Veh and LXA4). Graph pad Prism
version 6 (San Diego, CA, USA) was used; p,0.05 was considered
statistically significant.
Results
Treatment with LXA4 reduces the growth of surgically
induced endometriotic lesions
Wild-type female C57BL/6J mice underwent surgery at
8 weeks of age and developed endometriotic lesions within a few
days, which increased in size over time. We analyzed lesion size
and gene expression profiles at days 3 and 21 after surgery. As
most consistent results were observed at day 21, data from this
time point are shown. Three weeks after surgery we examined the
presence and growth of endometriotic lesions in the peritoneal
cavity of sham-operated control mice, vehicle-treated mice with
endometriosis (‘Veh’) and LXA4-treated mice with endometriosis
(‘LXA4’). Veh mice developed cyst-like lesions implanted on the
peritoneal wall surrounded by adhesions to adjacent organs,
validating our in vivo experimental model. No such structures were
observed in sham-operated mice. A significant reduction in lesion
volume was observed in LXA4 compared to Veh mice (Figureoˆ 1).
Macroscopic histological examination of the lesions from Veh
mice confirmed the presence of endometriotic glands surrounded
by stroma. Treatment with LXA4 resulted in a more rudimentary
architecture with less developed glands surrounded by little stroma
(Figureoˆ 1).
LXA4 attenuates pro-inflammatory and pro-angiogenic
mediators in endometriotic lesions and PFCs
We next investigated the mechanisms by which LXA4 treatment
controlled the development of endometriotic lesions and the
resulting inflammatory response. Genes involved in the initiation
of inflammatory pathways were analysed by qPCR. At day 21, we
observed significantly reduced IL-1b and IL-6 mRNA expression
in endometriotic lesions and PFCs from LXA4-treated (Figureoˆ 2A,
2B, 2H, 2I) compared to Veh mice. In the absence of
endometriosis i.e in sham mice, we didn’t observe any noticeable
effect of LXA4 on the main inflammatory mediators in initial
experiments (data not shown), and therefore to conserve mice, this
group was not included in subsequent experiments. LXA4 signals
via ALX/FPR2, a G protein-coupled receptor, in many cell types
including epithelial cells as well as innate immune cells such as
macrophages and neutrophils. This receptor was significantly
attenuated by LXA4 treatment in both lesions and peritoneal fluid
cells (Figureoˆ 2C, 2J).
Under hypoxic and inflammatory conditions the Hypoxia-
inducible factor-1a (HIF-1a) complex binds to hypoxia responsive
elements leading to the transcriptional activation of many target
genes including the pro-angiogenic mediator VEGF [27,28].
Upon LXA4 treatment, we observed inhibition of HIF-1a
expression (Figureoˆ 2D, 2K) and its target gene VEGF
(Figureoˆ 2F, 2M) in both endometriotic lesions and PFCs,
respectively. The activation of VEGF is also regulated by E2
and in turn induces cyclooxygenase-2 (COX-2) expression. LXA4
treatment resulted in a significant reduction in COX-2 expression
in endometriotic lesions (Figureoˆ 2E) and PFCs (Figureoˆ 2L).
Interestingly, LXA4 also downregulated the expression of the
multidrug resistance protein 4 (MRP4/ABCC4), which transports
PGE2 into the extracellular space [29], in endometriotic lesions
(Figureoˆ 2G) and PFCs (Figureoˆ 2N).
We observed consistently elevated transcript levels of pro-
inflammatory cytokines (IL-1b, IL-6) as well as ALX/FPR2, HIF-
1a, COX-2, VEGF and MRP4 in PFCs of Veh- mice to compared
to sham-operated mice (Figureoˆ 2H-2N), further confirming the
implication of these mediators in the pathogenesis of disease.
LXA4 reduces peritoneal fluid pro-inflammatory cytokine
and PGE2 levels, as well as COX-2 expression in lesions
and peritoneal fluid cells
To confirm the qPCR data and further investigate the role of
inflammation and angiogenesis in the development of endometri-
osis in our experimental model, IL-1b and VEGF contents in the
peritoneal fluid were measured at the protein level by ELISA and
found to be higher in veh-treated mice compared to sham
(Figureoˆ 3A, 3B). Indeed, LXA4 treatment resulted in a significant
reduction in the levels of these cytokines (Figureoˆ 3A, 3B).
Moreover, PGE2 was significantly higher in Veh-treated mice
compared to sham and reduced in the peritoneal fluid of LXA4
compared to Veh-treated mice (Figureoˆ 3C). We therefore
performed immunohistochemical staining for COX-2 on endome-
triotric lesions. Intense COX-2 staining was mainly observed in
the cytoplasm of stromal cells and macrophages, the latter cell type
was also confirmed as F4/80 positive by immunohistochemical
analysis (data not shown). LXA4 treatment attenuated the
expression of COX-2 protein in endometriotic lesions in
comparison to Veh-treated mice (Figureoˆ 3D).
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Figure 1. Treatment with LXA4 decreases endometriotic lesion growth. A. Representative pictures of a mouse with endometriotic lesions
treated with vehicle (Veh, left panel) or LXA4 (right panel) for 21 days. Six uterine biopsies were implanted on the peritoneal wall, 3 on each side, in a
minimum of 20 mice which were randomly divided into two groups: Veh- and LXA4-treated. Implanted tissues grew into enlarged cyst-like lesions by
21 days after endometriosis induction in the Veh group, while LXA4 treatment significantly reduced lesion size. B. Graphical representation of
endometriotic lesions volume, in mm36 SEM (**p,0.01). C.Morphology of formalin-fixed, paraffin-embedded lesion sections stained with HE. Upper
panels a. and b. Vehicle-treated mouse with endometriosis. Lower panels c. and d. LXA4-treated mouse with endometriosis. Images are representative
of ten biological replicates.
doi:10.1371/journal.pone.0089742.g001
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LXA4 modulates the expression of matrix remodelling
mediators in endometriotic lesions and PFCs
Matrix metalloproteinases (MMPs) are involved in extracellular
matrix degradation. In physiological conditions, macrophages are
recruited to the peritoneal cavity to phagocytose the retrograded
menstrual tissue [30,31]. MMPs, and in particular MMP-9,
facilitate the degradation of type IV collagen-containing basement
membrane of extracellular matrix that separates the epithelial and
stromal compartment. In our in vivo model, we analyzed MMP
expression at day 21 in endometriotic lesions and PFCs.
Treatment with LXA4 downregulated MMP-2 (Figureoˆ 4A) and
MMP-3 (Figureoˆ 4B) but upregulated MMP-9 (Figureoˆ 4C)
mRNA expression in endometriotic lesions. The expression of
MMP-2 (Figureoˆ 4G) and MMP-9 (Figureoˆ 4H) was, however,
similarly downregulated in PFCs by LXA4 treatment. Because of
this differential expression, we further analysed MMP-2 and
MMP-9 at the functional level. Enzymatic assay of peritoneal fluid
samples confirmed increased MMP-9 activity (Figureoˆ 5A, 5B)
under these conditions, whereas MMP-2 activity remained
unchanged (Figureoˆ 5C, 5D).
Transforming growth factor beta (TGF-b) is a pleiotropic factor
which is implicated in cell proliferation, differentiation, apoptosis,
as well as in immune regulation. TGF-b1 and 3 are expressed in
epithelial and stromal cells, while TGF-b2 is mainly expressed in
Figure 2. LXA4 significantly attenuates the expression of pro-inflammatory cytokines, angiogenic mediators, COX-2 and the PGE2
transporter MRP4. A. IL-1b, B. IL-6, C. FPR2, D. HIF-1a, E. COX-2, F. VEGF and G. MRP4 mRNA expression in endometriotic lesions was analyzed by
qPCR. H. IL-1b, I. IL-6, J. FPR2, K. HIF-1a, L. COX-2,M. VEGF and N. MRP4 mRNA expression was similarly quantified in PFCs. Ten mice were used per
group (Sham, Veh-, LXA4-treatment) and samples analyzed for each individual mouse. Mice were sacrificed 21 days after endometriosis induction and
Veh- or LXA4-treatment. Endometriotic lesions and PFCs were collected for RNA isolation and qPCR. Data were normalized to GAPDH and are
presented as mean 6 SEM (*p,0.05, **p,0.01, ***p,0.001 compared to Veh; fff p,0.001 compared to Sham).
doi:10.1371/journal.pone.0089742.g002
Figure 3. LXA4 reduces peritoneal fluid cytokine and PGE2 levels as well as the expression of COX-2 in endometriotic lesions.
Peritoneal fluid from mice was collected at sacrifice (Sham, Veh-, LXA4; 3–5 mice/group) and ELISAs performed to quantify A. IL-1b, B. VEGF and C.
PGE2 levels. Results are expressed as pg mediator/ml for 50 mg of total peritoneal fluid protein and presented as mean 6 SEM (*p,0.05, ***p,0.001
compared to Veh; f,0.05 compared to Sham). D. Immunohistochemical staining for COX-2 was performed on transverse paraffin-embedded
sections of lesions from Veh- and LXA4-treated mice. Representative stainings are shown with the negative control in the inset.
doi:10.1371/journal.pone.0089742.g003
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the stroma [32]. In endometriotic lesions and PFCs, LXA4
treatment reduced TGF-b1 (Figureoˆ 4D, 4I) and TGF-b2
(Figureoˆ 4E, 4J) expression. However, TGF-b3 (Figureoˆ 4F)
expression was augmented upon LXA4 in endometriotic lesions
only, while it was not detected in PFCs.
LXA4 inhibits estrogen regulated genes in endometriotic
lesions and PFCs
Estrogen production occurs from C19 steroids by the enzymatic
activity of aromatase (CYP19a1) and is involved in the estab-
lishment and maintenance of endometriotic lesions [2,33].
Figure 4. LXA4 significantly inhibits the expression of matrix remodeling genes. A. MMP-2, B. MMP-3, C. MMP-9, D. TGF-b1, E. TGF-b2, F.
TGF-b3, G. MMP-2, H. MMP-9, I. TGF-b1, J. TGF-b2 gene expression in lesions and PFCs. Ten mice were used per group (Sham, Veh-, LXA4-treatment)
and sacrificed 21 days after endometriosis induction. Lesions and PFCs were collected for qPCR analyses. Data were normalized to GAPDH and
presented as mean 6 SEM (***p,0.001 compared to Veh; ff p,0.01, fff p,0.001 compared to Sham).
doi:10.1371/journal.pone.0089742.g004
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Interestingly, LXA4 downregulated CYP19a1 (Figureoˆ 6A) in
endometriotic lesions. Aromatase mRNA expression was unde-
tectable in PFCs and it was also not possible to detect estrogens in
the corresponding peritoneal fluid using a sensitive LC MS/MS-
based method (data not shown). Lesions do not provide sufficient
material for such analyses. Estrogen receptor alpha (ERa)
expression was likewise attenuated by LXA4 in lesions and PFCs
(Figureoˆ 6B, 6F). Immunohistochemical analyses of ERa in lesions
yielded similar results at the protein level (Figureoˆ 6I). Further-
more, LXA4 augmented PR expression in lesions (p,0.001, data
not shown), while PR was undetectable in PFCs. Of note, as
assessed by performing vaginal smears, cycling was not impacted
in LXA4-treated mice (data not shown).
Cellular proliferation is a key factor underlying endometriosis
development and progression [34]. Estrogens could promote
endometrial tissue proliferation by activating specific genes
involved in the cell cycle. An important gene in this respect is
cyclin D1 (CCND1), involved in the regulation of G/S transition
during the cell cycle [35]. c-Myc, a transcription factor, regulates a
wide array of genes implicated in cell growth, proliferation and loss
of differentiation [36,37]. Notably, LXA4 attenuated mRNA
expression of both CCND1 (Figureoˆ 6D and 6G) and c-Myc
(Figureoˆ 6E and 6H) in endometriotic lesions and PFCs,
respectively. In addition, the expression of the gene regulated by
estrogen in breast cancer 1 (GREB1), involved in cell proliferation
[38], was reduced in endometriotic lesions in LXA4-treated mice
(Figureoˆ 6C). As would be expected for an epithelial molecule [38–
40], GREB1 mRNA was undetectable in PFCs. These data
provide further insight into the mechanisms leading to decreased
lesion size that we observed upon LXA4 treatment.
LXA4 treatment also results in reduced progression of
established endometriotic lesions
Patients attending Gynecology clinics because of pain and/or
fertility problems already have some degree of endometriosis. To
reflect this scenario and to determine whether our findings were
therapeutically relevant, we investigated the effect of once-daily
LXA4 treatment on established lesions. LXA4 treatment was thus
commenced either the day prior to surgery (D21) or on
postoperative day 6 (D+6), a time-point when lesions on the
peritoneal wall are already well developed. Interestingly, LXA4
reduced endometriotic lesion volume in established disease, i.e.
when given from D+6 (Figureoˆ 7A). We then selected
representative genes for the different pathways that we had
observed to be implicated in the pathogenesis of endometriosis in
our in vivo model, namely inflammation, angiogenesis, PGE2
production and transport, matrix remodeling and estrogen
signaling. As observed when LXA4 was administered on D21,
IL-1b, COX-2, VEGF, MRP4, TGF-b1, TGF-b2, CYP19a1,
ERa, GREB1 and c-Myc expression were significantly attenu-
ated whereas MMP-9 and TGF-b3 were upregulated in
endometriotic lesions in established endometriosis (Figureoˆ 7Ba-
l). Gene expression profiling of PFCs yielded similar results (data
not shown). IL-1b and VEGF protein levels in the peritoneal
fluid were also significantly reduced by LXA4 treatment in both
de novo and established disease (Fig.oˆ 7Ca, b).
Discussion
In the present study we examined the effect of LXA4 on the IL-
1b-COX-2-PGE2-VEGF axis as well as on ERa and E2-regulated
genes implicated in an experimental endometriosis model. It has
been reported that the proliferation of ectopic endometrial tissue is
influenced by various cytokines, lipid mediators and growth factors
present in the peritoneal fluid. The ectopic endometrium itself
may also produce pleiotropic factors promoting its survival and
growth [2,7]. The mechanisms by which endometrial tissues
attach, proliferate, avoid immune surveillance and derive a local
vasculature at ectopic sites are not well understood. We thus
investigated various mediators in the peritoneal fluid, as well as in
PFCs and endometriotic lesions in a mouse model of disease.
Lipoxins are endogenous eicosanoids produced during inflam-
matory events by platelet-leukocyte and leukocyte-epithelial
interactions. Their anti-inflammatory and pro-resolving properties
have been well described [41]. Using a surgically induced
endometriosis model [25,42], we first showed that treatment with
LXA4 reduced the volume of endometriotic lesions in part by
attenuating pro-inflammatory (IL-1b and IL-6) and pro-angio-
genic (VEGF) mediators in endometriotic lesions and PFCs. Our
results confirm and extend previous reports describing the
inhibitory effect of LXA4 and a stable analogue on the
development of endometriotic lesions [22,23,43], using a different
murine experimental model where endometrial tissue fragments
were injected into the peritoneum.
Inflammatory, hypoxic and metabolic conditions lead to HIF
activation and the induction of VEGF expression [44], a feature of
endometriosis pathology [45,46]. We observed this pathway to be
Figure 5. Gelatin zymography analysis of MMP-2 and MMP-9
activity. A. Representative gel showing gelatinolytic activities of A.
MMP-9, and C. MMP-2 in peritoneal fluid of Veh- and LXA4-treated mice
(3–4 mice/group). Bar graphs represent the densitometric quantification
of B. MMP-9 and D. MMP-2 activity, respectively. Unpaired t-tests were
performed for comparison with the corresponding Veh-treatment
group (**p,0.01).
doi:10.1371/journal.pone.0089742.g005
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Figure 6. Mediators implicated in estrogen production and cellular proliferation in endometriotic lesions and PFCs are inhibited by
LXA4 treatment. mRNA was extracted from endometriotic lesions and PFCs and subjected to qPCR analysis to assess transcript levels of A.
CYP19a1, B. ERa, C. GREB1, D. CCND1, E. c-Myc and F. ERa, G. CCND1, H. c-Myc, respectively. Results were normalized to GAPDH. Ten mice were
used per group (Sham, Veh-, LXA4-treatment) and sacrificed 21 days after surgical induction of endometriosis. Data are presented as mean 6 SEM.
(***p,0.001 compared to Veh; fff p,0.001 compared to Sham). I. Immunohistochemical staining for ERa was performed on transverse sections of
endometriotic lesions from Veh- (left panel) and LXA4-treated (right panel) mice. The negative control is shown in the inset.
doi:10.1371/journal.pone.0089742.g006
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activated in endometriosis and LXA4 attenuated the expression of
HIF-1a mRNA in endometriotic lesions and PFCs. Among the
angiogenic factors, VEGF-A is the most studied and patients with
endometriosis have increased VEGF levels in their peritoneal fluid
compared to the peritoneal fluid and eutopic endometrium of
healthy women [46,47]. VEGF is thus involved in the pathogen-
esis of endometriosis and the inhibition of VEGF and/or its
receptor may be a potential therapeutic target for the treatment of
endometriosis as investigated in various animal models [45,48–
50]. In line with these findings, we observed that LXA4
significantly downregulated VEGF-A mRNA levels in endometri-
otic lesions and PFCs, as well as VEGF-A protein in the peritoneal
fluid. These data suggest that LXA4’s anti-angiogenic capacity
results in decreased lesion size, corroborating previously published
data [22,23].
COX-2, the rate limiting enzyme in PGE2 biosynthesis, is
increased in ectopic and eutopic endometrial tissues of endome-
triosis patients compared to healthy controls by cytokines such as
IL-1b [51,52]. PGE2 in turn strongly induces CYP19a1 (Aroma-
tase), thus creating a positive feedback mechanism that maintains
elevated local estradiol levels [2,53,54]. We observed elevated
COX-2 expression in the lesions and PFCs of Veh-treated
compared to sham mice. COX-2 expression in PFCs and
endometriotic lesions was down-regulated upon LXA4 treatment.
This was confirmed by immunohistochemical analyses, revealing
markedly more intense COX-2 staining in endometriotic stromal
cells and macrophages within lesions of Veh-treated compared to
LXA4-treated mice. Furthermore, as compared to Veh-treated
mice, LXA4 decreased CYP19a1 expression in endometriotic
lesions, this coincided with decreased expression of E2-regulated
molecules involved in cellular proliferation. We have recently
demonstrated that the PGE2 transporter MRP4, a potential
biomarker, is upregulated in peritoneal endometriosis in women,
and that its expression is attenuated by LXA4 in vitro, signaling via
ERa [55]. Here, we confirm those findings in vivo. The expression
of MRP4, which functions to actively transport PGE2 and other
molecules into the extracellular environment [29], was reduced in
endometriotic lesions and PFCs, consistent with the decreased
PGE2 peritoneal fluid levels. These findings support the hypothesis
that LXA4 controls endometriotic lesion growth by inhibiting
PGE2 production and it’s efflux into the extracellular space where
it could bind its receptors and initiate signaling pathways,
resulting, in turn, in blunted estrogen production and proliferative
mediator expression. It is tempting to speculate that the attenuated
CYP19a1 expression we observed is due to decreased local PGE2
levels, this novel observation warrants further study to determine
whether LXA4 downregulates CYP19a1 expression via this
mechanism or via direct transcriptional repression.
Estrogen production and signaling are considered central to the
pathogenesis of endometriosis [2,7,25]. Accordingly, in our
surgically induced model using mice with intact uteri and ovaries,
we observed increased CYP19a1, ERa and COX-2 expression in
the endometriotic lesions of Veh-treated mice as well as increased
PGE2 peritoneal fluid levels compared to sham mice, which were
reduced in LXA4-treated animals. As ERa is dynamically
regulated, we studied estrogen signaling by assessing the impact
of LXA4 on the downstream effectors c-Myc, CCND1 and
GREB1, key regulators of cell cycle progression and cellular
proliferation, whose dysregulated expression and activation has
been implicated in the pathogenesis of human cancers
[36,37,40,56], and in endometriotic cell proliferation [57–59].
GREB1, which we have shown is upregulated in peritoneal
endometriosis [39], was also identified in genome wide association
studies as containg a risk locus [60].
c-Myc is additionally considered a key player in alternative
macrophage polarization [61]. We and others have reported that
these molecules were overexpressed in peritoneal lesions and
eutopic endometrium of endometriosis patients in comparison to
control subjects [39,62,63]. In PFCs, CCND1 and c-Myc
expression was higher in Veh-treated mice compared to control
sham mice, suggesting a role in disease development. Interestingly,
LXA4 treatment attenuated the expression of c-Myc, CCND1 and
GREB1 in endometriotic lesions and that of c-Myc and CCND1
in PFCs. ERa was also reduced in both compartments. This data
is in line with with our recent characterization of LXA4 as an
estrogen receptor ligand, which can inhibit endogenous E2-
mediated signaling under certain circumstances in a manner
similar to the weak estrogen Estriol [64,65], with which it shares
structural similarity [18]. Hence, these results indicate that LXA4
exerts a local anti-proliferative effect, possibly via ERa, a receptor
essential for endometriosis development in mice [66]. ALX/FPR2
to which LXA4 binds with high affinity and whose expression is
upregulated under inflammatory conditions in in vitro experimental
models [67] as well as in tissue biopsies from patients with
inflammatory diseases [68], was also increased in lesions after
surgical induction of endometriosis as assessed by a previous gene
array analysis [69]. This receptor was significantly attenuated by
LXA4 treatment in both lesions and peritoneal fluid cells,
indicating either a reduction in receptor expression on cells in
situ or decreased migration of ALX/FPR2-positive cells into these
compartments.
To further understand the progression of the disease and the
beneficial effects of LXA4 treatment, we analysed the expression of
TGF-b, a mediator involved in cell proliferation and differenti-
ation as well as in tissue repair. TGF-b is highly expressed in the
endometrium and is secreted by endometrial glands and macro-
phages [32,70]. Patients with endometriosis have higher levels of
TGF-b1 in the peritoneal fluid compared to disease-free subjects
[10,71] and higher TGF-b2 mRNA expression was reported in the
ectopic endometriotic lesions [72]. In our study, LXA4 differen-
tially regulated TGF-b isoforms. Upon LXA4 treatment, the
expression of TGF-b1 and 2 was attenuated in endometriotic
lesions and PFCs, whereas TGF-b3 expression was upregulated in
the same compartments. These findings merit further investigation
as, besides being a growth factor, TGF-b was shown to be essential
in wound healing and tissue repair by inducing extracellular
matrix components [73]. We also assessed the activity of MMPs,
involved in extracellular matrix degradation and thereby likely
contributing to the local invasiveness of the lesions. Of note, Wu
et al., reported that high levels of PGE2 in the peritoneal cavity of
endometriotic patients inhibited MMP-9 activity, thus interfering
with the clearance of endometrial tissue [21]. We observed
Figure 7. LXA4 reduces the progression of established endometriosis by similar mechanisms. Peritoneal endometriosis was surgically
induced in mice divided into 3 groups (n = 7/group): Veh or LXA4 (5 mg/kg/mouse once daily) was administered from the day prior to surgery D(21),
or started at postoperative day 6 D(+6). Treatment was continued until day 21 after surgery, when the mice were sacrificed. A. Endometriotic lesion
volume expressed as mean mm3 6 SEM (**p,0.01). B. a. IL-1b, b. COX-2, c. VEGF, d. MRP4, e. MMP-9, f. TGF-b1, g. TGF-b2, h. TGF-b3, i. CYP19a1, j.
ERa, k. GREB1 and l. c-Myc mRNA expression was quantified in endometriotic lesions by qPCR and normalized to GAPDH. C. a. IL-1b and b. VEGF
protein concentrations in the peritoneal fluid were measured by ELISA and expressed as pg/ml. All data are presented as mean 6 SEM. Unpaired t-
tests were performed for comparisons with the corresponding Veh-treated group (*p,0.05 **p,0.01, ***p,0.001, ip,0.05, i ip,0.01, i i ip,0.001).
doi:10.1371/journal.pone.0089742.g007
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elevated MMP-9 expression in endometriotic lesions, but not in
PFCs, of LXA4-treated mice, where it was decreased. On a
functional level, MMP-9 activity in this environment was
increased, possibly contributing to decreased lesion size. However,
these molecules are regulated in a complex manner and our
findings likely reflect the expression patterns of the various TGF-b
isotypes and MMP subtypes which may be both differentially
regulated and compartmentalized as a function of specific
anatomical sites and cell types during the course of disease.
Current standard medical treatments for endometriosis include
therapies that control the production of estrogens alone or in
combination with anti-inflammatory drugs [74,75]. However, as
well as being partially effective these treatments have considerable
systemic side-effects including a hypo-estrogenic state that may
lead to osteoporosis, as well as impaired fertility. Much published
data suggest that endometriosis is a local rather than a systemic
phenomenon with the induction of a local microenvironment in
the peritoneal cavity which promotes ectopic lesion growth. We
have demonstrated that LXA4 inhibits the progression of
endometriosis via multiple local mechanisms. In this context,
LXA4 regulates mediators which are responsible for diverse
biological activities such as inflammation (IL-1b, IL-6, COX-2,
PGE2), cell survival and proliferation (PGE2, CYP19a1, CCND1,
c-Myc, GREB1), cell adhesion and invasion (MMPs, TGF-b) and
angiogenesis (HIF-1a, VEGF, TGF-b). Further investigations are
necessary to delineate whether the anti-inflammatory effects of
LXA4 are directly exerted on epithelial and stromal cells and/or
via trafficking immune cells. As macrophages are major sources of
pro-inflammatory cytokines and PGE2, the subsets in the
peritoneal cavity and in the lesions necessitate elucidation.
LXA4 inhibited the progression of endometriosis by attenuating
local estrogen-mediated signaling in endometriotic lesions and in
peritoneal fluid cells, and most likely reducing estrogen produc-
tion. This, without affecting the estrous cycle as was also previously
reported [22] or evoking any other noticeable adverse effects. We
also made the novel and clinically relevant observation that LXA4
was effective when administered in the context of established
disease. Taken together, LXA4 and its stable analogues warrant
further consideration as potential therapeutics for the treatment of
peritoneal endometriosis.
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